Literature DB >> 11192924

Surgical complications after primary nephrectomy for Wilms' tumor: report from the National Wilms' Tumor Study Group.

M L Ritchey1, R C Shamberger, G Haase, J Horwitz, T Bergemann, N E Breslow.   

Abstract

BACKGROUND: Surgical complications are a recognized morbidity of the treatment of patients with Wilms tumor. This study examines the incidence of surgical complications in the most recently completed study from the National Wilms' Tumor Study Group (NWTSG). STUDY
DESIGN: The fourth National Wilms' Tumor Study (NWTS-4) enrolled 3,335 patients from August 1986 to August 1994. A random sample of 534 patients was selected from 2,290 eligible patients randomized to treatment regimens or enrolled in the followed category and treated according to NWXTSG protocol. The patient records received at the NWTSG Data and Statistical Center were analyzed for surgical complications (intraoperative and postoperative).
RESULTS: Sixty-eight patients (12.7%) experienced 76 complications. Intestinal obstruction was the most common complication (5.1% of patients), followed by extensive hemorrhage (1.9%), wound infection (1.9%), and vascular injury (1.5%). The incidence of surgical complications in NWTS-4 was significantly lower than NWTS-3 (12.7% versus 19.8%, p < 0.001). There has been a marked decrease in the risk of extensive intraoperative bleeding and major intraoperative complications. Factors previously shown to be associated with an increased risk for surgical complications, together with indicators of type of hospital and surgeon specialty, were analyzed by multiple logistic regression analysis. Intravascular extension into the inferior vena cava (IVC), the atrium, or both (p = 0.02; odds ratio [OR] 3.8, 95% confidence interval [CI] 1.2, 11.8), and nephrectomy performed through a flank or paramedian incision (p = 0.02; OR 5.3, 95% CI 1.3, 22) were both associated with increased risk of complications. Tumor diameter greater than or equal to 10cm was also associated with an increased risk of surgical complications (p = 0.05; OR 2.0, 95% CI 1.0, 3.9). The risk of complications was higher if the nephrectomy was performed by a general surgeon (OR 9.0, 95% CI 1.3, 65; p = 0.03) rather than a pediatric surgeon (reference group, OR 1.0) or pediatric urologist (OR 0.7, 95% CI 0.3, 1.8).
CONCLUSIONS: The incidence of surgical complications in NWTSG patients undergoing primary nephrectomy has significantly decreased over the past decade. But surgical morbidity should not be overlooked. It is important that surgeons treating young children with solid tumors are aware of their role and the potential risks encountered in removal of the primary tumor. This study found that surgical specialists who primarily treat children can perform these operations with lower surgical morbidity.

Entities:  

Mesh:

Year:  2001        PMID: 11192924     DOI: 10.1016/s1072-7515(00)00749-3

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  31 in total

1.  Outcomes of children with favorable histology wilms tumor and peritoneal implants treated in National Wilms Tumor Studies-4 and -5.

Authors:  John A Kalapurakal; Daniel M Green; Gerald Haase; James R Anderson; Jeffrey S Dome; Paul E Grundy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-01       Impact factor: 7.038

Review 2.  Nephron-sparing surgery for Wilms tumor: A systematic review.

Authors:  Rand N Wilcox Vanden Berg; Emily N Bierman; Megan Van Noord; Henry E Rice; Jonathan C Routh
Journal:  Urol Oncol       Date:  2015-08-05       Impact factor: 3.498

3.  [Childhood kidney tumors -- the relevance of imaging].

Authors:  J-P Schenk; P Günther; C Schrader; S Ley; R Furtwängler; I Leuschner; M Edelhäuser; N Graf; J Tröger
Journal:  Radiologe       Date:  2005-12       Impact factor: 0.635

Review 4.  [Computer-assisted operational planning for pediatric abdominal surgery. 3D-visualized MRI with volume rendering].

Authors:  P Günther; J Tröger; S Holland-Cunz; K L Waag; J P Schenk
Journal:  Radiologe       Date:  2006-08       Impact factor: 0.635

5.  [Wilms tumor].

Authors:  F Seseke; P Gutjahr; B Kremens
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

Review 6.  Internal hernia through the descending mesocolon following left radical nephrectomy--a rare complication: case report and review of the literature.

Authors:  A Kumar; V Trehan; T S Ramakrishnan; V Maheshwari
Journal:  Hernia       Date:  2010-08-22       Impact factor: 4.739

7.  Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.

Authors:  Conrad V Fernandez; Elizabeth A Mullen; Yueh-Yun Chi; Peter F Ehrlich; Elizabeth J Perlman; John A Kalapurakal; Geetika Khanna; Arnold C Paulino; Thomas E Hamilton; Kenneth W Gow; Zelig Tochner; Fredric A Hoffer; Janice S Withycombe; Robert C Shamberger; Yeonil Kim; James I Geller; James R Anderson; Paul E Grundy; Jeffrey S Dome
Journal:  J Clin Oncol       Date:  2017-12-06       Impact factor: 44.544

8.  HER2/neu expression: a predictor for differentiation and survival in children with Wilms tumor.

Authors:  Seham M Ragab; Rehab M Samaka; Tahany M Shams
Journal:  Pathol Oncol Res       Date:  2009-07-17       Impact factor: 3.201

9.  Image-based surgical risk factors for Wilms tumor.

Authors:  Takaharu Oue; Akihiro Yoneda; Noriaki Usui; Takashi Sasaki; Masahiro Zenitani; Natsumi Tanaka; Shuichiro Uehara; Soji Ibuka; Yuichi Takama; Hiroomi Okuyama
Journal:  Pediatr Surg Int       Date:  2017-11-08       Impact factor: 1.827

10.  Primary nephrectomy and intraoperative tumor spill: report from the Children's Oncology Group (COG) renal tumors committee.

Authors:  Kenneth W Gow; Douglas C Barnhart; Thomas E Hamilton; Jessica J Kandel; Mike K S Chen; Fernando A Ferrer; Mitchell R Price; Elizabeth A Mullen; James I Geller; Eric J Gratias; Nancy Rosen; Geetika Khanna; Arlene Naranjo; Michael L Ritchey; Paul E Grundy; Jeffrey S Dome; Peter F Ehrlich
Journal:  J Pediatr Surg       Date:  2013-01       Impact factor: 2.545

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.